RxDoctor Payments DataLook up a doctor →

Rubylyn Hilario

Family · Elgin, ILNPI 1952862104

Payments from drug & device makers

$18,273in general payments, 2019–2025

Across 875 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$3K
  • Novo Nordisk$2K
  • Dexcom, Inc.$2K
  • Boehringer Ingelheim$1K
  • Amneal Pharmaceuticals LLC$1K
  • Amgen$1K
  • plus $8K from 41 others

What the payments were for

  • Food & beverage$18,12899%
  • Education$1461%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,273 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$34,675
Medicare patients
191
Services billed
420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide223$300,478
JardianceEmpagliflozin194$190,167
TrulicityDulaglutide64$83,227
MounjaroTirzepatide64$67,373
Tresiba Flextouch U-100Insulin Degludec80$56,557
FarxigaDapagliflozin Propanediol45$41,814
Tresiba Flextouch U-200Insulin Degludec18$37,870
Synjardy XrEmpagliflozin/Metformin Hcl28$36,076
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog29$23,477
Lyumjev Kwikpen U-100Insulin Lispro-Aabc21$17,106
Xigduo XrDapaglifloz Propaned/Metformin14$16,082
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog28$15,717
Fiasp FlextouchInsulin Aspart (Niacinamide)13$10,958
Gvoke Hypopen 2-PackGlucagon13$8,221
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$7,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,157$300,478223 claims
Boehringer IngelheimJardiance, Synjardy Xr$1,399$226,243222 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$2,799$154,625147 claims
AstraZenecaFarxiga$687$41,81445 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$1,182$10,339530 claims
IBSA Pharma Inc.Tirosint-Sol$514$3,09111 claims
AbbVieSynthroid$213$3,00149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Elgin

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →